anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Composition including freeze thaw stability polymer such as a copolymer having a weight average molecular weight of at least about 30,000 grams per mole, a blend of a first polymer and a second polymer, a crosslinked alkali swellable acrylate copolymer, or at least one polymehzable reactive alkoxylated acrylate monomer. The copolymer has one or more first monomeric units and one or more second monomeric units. The one or more first monomeric units each independently including at least one bicycloheptyl-polyether, bicycloheptenyl-polyether or branched (C 5 -C 50 )alkyl-polyether group per monomeric unit. The bicycloheptyl-polyether or bicycloheptenyl-polyether group may optionally be substituted on one or more ring carbon atoms by one or two (C 1 C 6 )alkyl groups per carbon atom. The one or more second monomeric units each independently including at least one pendant linear or branched (C 5 -C 50 )alkyl-polyether group per monomeric unit. The first and second monomeric units do not both have branched (C 5 -C 50 )alkyl-polyether group.
Data generated by this study will provide a snapshot of the current situation regarding P. falciparum sensitivity to ACTs in Western Kenya. By having subjects in one of the study arms receive artesunate and then the partner drug after completion of the artemisinin phase will enable the accurate evaluation of the artemisinin derivative without the confounding influence of the partner drug. Sequential administration of the components of an ACT drug is recognized by the WHO as one of the ways in which ACTs can be administered. There will be close follow-up of the subjects throughout the duration of the study, and as such, subjects who fail to respond adequately will receive prompt rescue treatment. Since it is largely expected that most subjects in Western Kenya will have satisfactory responses to ACTs, data from this study will provide baseline information regarding parasite characteristics when compared to data from Thailand, an area that has reported resistance to ACTs. This, in turn, will potentially enable the identification of key markers, both in the host and the parasite, that may assist in the early detection of resistance, and also to better understand the development of resistance to ACTs. As such, the data generated from this study, both on its own and when compared to and pooled with data from similar studies that will be conducted in Peru and Thailand, will potentially inform both local and international policy regarding ACT use for the treatment of uncomplicated P. falciparum malaria.
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease that mainly affects children and adolescents. Clinical presentations range from mild and sometimes limited unifocal disease to severe, chronically active or recurrent inflammation of multiple bones. The latter is referred to as chronic recurrent multifocal osteomyelitis (CRMO). Here we will use the term "CNO" to refer to the entire spectrum of this disease. CNO can be complicated by vertebral compression fractures, kyphosis, and leg length discrepancy when it is not recognized early or treated adequately. The diagnosis of CNO is made by excluding alternatives in the differential diagnosis including malignancy (leukemia, lymphoma, and primary or metastatic bone tumors), Langerhans cell histiocytosis, and infection. Clinical assessment in conjunction with serum inflammatory parameters and imaging studies, particularly magnetic resonance imaging (MRI), are crucial for the diagnosis and monitoring of disease activity of CNO1.

Because of significant variation in clinical treatment practices among pediatric rheumatologists, standardized treatment regimens (consensus treatment plans, CTPs) have been developed within the Childhood Arthritis and Rheumatology Research Alliance (CARRA), a North American organization comprised of pediatric rheumatologists and researchers, for CNO patients with an NSAID-refractory course and/or with active spinal lesions2. These CTPs provide an opportunity for pediatric rheumatologists to conduct comparative effectiveness research on CNO through prospective data collection. CRMO/CNO workgroup is comprised of pediatric rheumatologists from North America as well as international colleagues who are interested in collaborating in CNO research. Furthermore, risk factors of severe disease have been described by Wipff et al. based on a large retrospective cohort study3. Their results may be validated by an independent prospective cohort study. To date, there has been only one prospective study on CNO since its first description in 19724. Therefore, we propose to establish this international registry of patients with CNO to accomplish above goals. Long-term outcomes of CNO remains unknown due to the lack of prospective study. It has been estimated that at least 50% of CNO patients continue to need medications for CNO during adulthood. Our study will collect the clinical data and provide valuable data to characterize the long-term outcomes.
Multiphase microspheres for use in radioactive embolization include two-phase microspheres and three-phase microspheres prepared by microfluidic methods. The multi-phase microspheres include a major phase and a first minor phase surrounded by the major phase. The primary phase includes a first resin. The first minor phase includes a second resin, and at least one of a radioisotope or a compound including at least one radioactive element. The three-phase microspheres additionally include a second secondary phase that is separated from the first secondary phase and is also surrounded by the primary phase. The second secondary phase may be a gas such as air. The microspheres may be formed by microfluidic methods.
FIELD: medicine, oncology. SUBSTANCE: agent contains pine and spruce coniferous needles lipid complex involving metal-derivatives of chlorophyll at amount 10-43% and physiologically acceptable additional agents and inert vehicles. Agent for cancer prophylaxis inhibits development and multiplicity of tumors on mamma and intestinum crassum cancer models by an average 20% and 48%, respectively. Preparation is given in 3 modifications. Proposed agent is prepared in tabletted form for prophylaxis mamma and intestinum crassum cancer. EFFECT: enhanced effectiveness of agent proposed.
Acute exercise, a single session of exercise, has been shown to enhance cognitive functions. The meta-analysis research has suggested that such benefits might depend upon the types of exercise. However, the predominant types of exercise examined within this area of research are aerobic and resistance exercises. The effects of other types of exercises on cognitive functions are poorly understood. Accordingly, this study is going to examine the effects of different types of acute exercise \[i.e., aerobic exercise (AE), aerobic exercise with virtual reality (AE-VR), and combined exercise (CE)\] on cognitive functions.

140-180 healthy young adults will be recruited and then randomly assigned to the AE, AE-VR, CE, and Control groups for a 35-minute intervention. Cardiovascular fitness will be assessed beforehand. Additionally, Stroop tasks and several questionnaires will be conducted before and after the intervention. The targeted primary outcomes are changes in cognitive behavior performance (assessed by the Stroop tasks) and neuroelectrical indices (e.g., P3 of event-related potential). The secondary outcomes are the changes in exercise enjoyment, motivation, and emotion.
It is necessary to monitor HIV over long periods of time in order to better understand the impact of microbicides and anti-HIV drugs on the progression of HIV infection in those who become infected or are unknowingly already infected while receiving these drugs. The purpose of this study is to determine the effects of microbicides or oral anti-HIV drugs over time in HIV infected women who were previously enrolled in other microbicide trials.

The study will remain open to accrual for the duration of MTN funding, and will use two follow-up visit schedules, one based on the date of diagnosis in the parent study, and one based on the initiation of antiretroviral treatment (ART). Participants who have not initiated ART at the time of enrollment in this study will follow the schedule based on the date of diagnosis. Participants who have already begun ART at the time of enrollment will follow the schedule based on the date of ART initiation. Individuals enrolled with a starting date based on the date of ART initiation will have their first follow-up visit at Week 2 before resuming the rest of the schedule. On both schedules, follow-up visits occur at Months 1, 3, and 6 and every 6 months thereafter. Interim visits may be performed at any time during follow-up, and participants will be asked to attend a final study visit prior to their termination from the study. Participants may enroll any time after their HIV diagnosis and can leave the study at any time.

A physical exam; medical and medication history assessment; blood and urine collection; and pelvic, cervicovaginal lavage, and vaginal swab sampling will occur at all visits. A behavioral assessment will occur at select visits, and adherence and social harms assessments will occur at most visits. Sexually transmitted infection risk reduction/contraception and HIV-1 secondary counseling will occur at most visits. In addition, condoms will be provided at all visits to reduce further HIV transmission. ART will not be provided by this study.
Following the OL Phase, participants who exhibited a Hamilton Rating Scale for Depression (HAM-D) response, defined as a greater than or equal to (≥) 50% reduction from baseline in HAM-D total score were to be randomized to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, in a total of five, 14-day treatment periods, each separated by a 6-week follow-up period during the 40-week DB Phase of the study. However, no participants were randomized to receive SAGE-217 matching placebo due to early study termination.
BACKGROUND/OBJECTIVES: The event-rate of recurrent acute pancreatitis (RAP) in patient populations is critical for powering research studies. We hypothesize that some patients manage RAP attacks at home, reducing event rate estimations based on counting emergency department (ED) visits and hospitalizations only. The aim of this study was to determine the rates of home self-management of recurrent acute pancreatitis compared to ED visits and hospitalizations.
METHODS: An anonymous 8-question survey was sent to 1825 individuals on an email list of individuals with a history of acute pancreatitis (AP) or chronic pancreatitis or interest in pancreatic diseases. Question were designed to identify subjects with RAP within the past 2 years and to subdivide patients based on having a chronic pain syndrome or not.
RESULTS: After an initial email request and one reminder a total of 194 subjects responded with 98 RAP subjects suitable for analysis. Annual AP events included an average of 1.44 hospitalizations, 1.37 ED visits, 2.46 disrupted work/school/social engagements, and 3.95 pancreatitis-like pain attacks per year. Patients with RAP average 6.8 RAP events per year with 58.4 % managed at home.
CONCLUSIONS: The burden of disease in patients with RAP is significantly underestimated, especially for patients with chronic pain. Future studies should include measures to capture RAP events managed at home and utilize methods of documenting RAP events.
For eligible children aged 0-4, inform parents about the condition and sign an informed consent form. Explain the specific sleep adjustment plan to help parents prepare the child for positioning and radiotherapy appointments.
The control group: Baby will be wrapped as standard treatment. Video recording will start 2 minutes before the baby is inserted into the orogastric catheter. The steps of the orogastric tube insertion procedure will be followed. The baby will be in an incubator during the application, with pulse and saturation monitored. No additional intervention will be applied to the baby.
The invention relates to tetracycline compounds having the following formulae <FORM:1065716/C2/1> in which X is H or CH3, X1 is OH or X and X1 together are methylene, or X1 represents a second bond connecting C6 and C5a, X2 is H or OH, X being CH3 when the C6-C5a bond is a single bond and/or X2 is OH and Y is H or Cl; and Z is H, Cl or F, X being CH3 when the 6-5a bond is a single bond and Z is H, or Z is halogen when X and X1 are together methylene; and when X1 is OH, the compound III may be in its 4-6 hemiketal form. <FORM:1065716/C2/2> wherein X, X1, X2 and Y have the aforesaid meanings <FORM:1065716/C2/3> wherein Z is H, Cl or F, X is CH3 or H, X2 is OH or H, with the proviso that X is CH3 when Z is H or X2 is OH; Y is H or Cl.  Also their salts.  Compounds of formula (A) are produced by reacting a compound of formula <FORM:1065716/C2/4> in which X, X1, X2, Y and Z have the aforesaid meanings, the 6-5a bond being a single bond, or in which the Z is halo and X1 is an oxygen connected to the 6 and 12 positions in a hemiketal bond, with a hydrocarbon dicarboxylic acid haloimide, e.g. N-chlorosuccinimide and, if X1 in compound III is a bond in the 6-5a position, dehydrating the product in which X1 is OH or an oxygen connected to C6 and C4 in a hemiketal bond.  Compounds of formula (B) are produced by reducing compounds of formula (A), e.g. with alkali metal hydrosulphite in aqueous alcohol.  The salts may be pharmaceutically acceptable, e.g. the sodium, potassium, magnesium, calcium, aluminium, zinc, iron and magnesium; metal chelates salts with amines.  Barium and strontium salts may be used in the isolation and purification of these compounds.
Introductory cohort to ensure participant safety, prior to the dose escalation study. 400 μg of RO7051790 was administered to two (2) participants followed by a 21-day DLT observation period.
The invention discloses an IL-15/SuIL-15R alpha-dFc-gamma 4 complex protein, which comprises an amino acid sequence shown in SEQ ID No.1 or an amino acid sequence with more than 90% of identity with the SEQ ID No. 1. The invention also discloses a construction method of the IL-15/SuIL-15R alpha-dFc-gamma 4 complex protein. The invention also discloses two expression vectors. The invention also discloses a yeast strain. The invention also discloses application of the IL-15/SuIL-15R alpha-dFc-gamma 4 complex protein in preparing antiviral and antitumor drugs. The invention also discloses application of the expression vector or the yeast strain in expression of IL-15/SuIL-15R alpha-dFc-gamma 4 complex protein. The complex protein significantly prolongs the half-life of IL-15.
Repeated paternal preconception exposure to Δ9-tetrahydrocannabinol (Δ9-THC) alone or together with the other constituents in a cannabis extract has been shown in our earlier studies in rats to cause significant neurobehavioral impairment in their offspring. In the current study, we compared the effects of daily cannabis extract (CE) exposure to cannabis on two consecutive days per week, modeling weekend cannabis use in human. The CE contained Δ9-THC as well as cannabidiol and cannabinol. We also extended the investigation of the study to cross-generational effects of grand-paternal cannabis exposure on the F2 generation and included testing the effects of paternal cannabis exposure on responding for opiate self-administration in F1 and F2 generation offspring. We replicated the findings of neurobehavioral impairment in F1 offspring of male rats exposed to cannabis extract containing 4 mg/kg/day of Δ9-THC daily for four weeks prior to mating with drug naïve females. The 4-week cannabis extract exposure caused a significant decrease in weight gain in the male rats exposed daily. In contrast, their offspring showed significantly greater body weights and anogenital distances (AGD) in the third to fourth weeks after birth. The behavioral effects seen in the F1 generation were increased habituation of locomotor activity in the figure-8 maze in female offspring and increased lever pressing for the opiate drug remifentanil in male offspring. The F2 generation showed significantly impaired negative geotaxis and an elimination of the typical sex-difference in locomotor activity, with effects not seen in the F1 generation. This study shows that daily paternal cannabis exposure for four weeks prior to mating causes significant neurobehavioral impairment in the F1 and F2 offspring. Intermittent exposure on two consecutive days per week for four weeks caused comparable neurobehavioral impairment. In sum, there should be concern about paternal as well as maternal exposure to cannabis concerning neurobehavioral development of their offspring.
Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care. Patients will receive all treatments (e.g. physical therapy) except the nutrition education.
The invention belongs to the technical field of biological medicines, and discloses a vaccine delivery vector, and a preparation method and application thereof. The vaccine delivery carrier is an immune adjuvant bonding polymer, and the structure of the vaccine delivery carrier is as follows. The invention also discloses a preparation method of the vaccine delivery vector. The vaccine delivery vectors of the invention are capable of delivering protein antigens into the cytoplasm of antigen presenting cells. The delivery carrier improves the efficiency of antigen cytoplasm delivery and effectively promotes the cross presentation of DC cell antigens. The vaccine delivery vector is used for preparing nano vaccines. The nano-vaccine comprises a vaccine delivery carrier and a protein antigen.The vaccine of the invention is a vaccine for preventing and/or resisting tumor. The vaccine inhibits the growth of tumors by inducing specific immune response, and has good specificity and high treatment efficiency.
The PG and JG were injected with autologous PRP at baseline. The injection was performed by the same clinician with 10 years of experience in knee joint injections. Participants were seated with their knees extended, and the needle was inserted through the joint space into the intra-articular cavity of the knee, administering approximately 2.5 mL of PRP into each knee joint. Thirty millilitres of venous blood were drawn from the participant's elbow vein, and approximately 5 mL of PRP was obtained for bilateral knee joint injection by using a TD5A tabletop low-speed centrifuge manufactured in China. The first centrifugation was performed at 2500 revolutions per minute (rpm) for 3 minutes, followed by a second centrifugation at 2300 rpm for 6 minutes.
This case-control study seeks to investigate the influence of histological findings, specifically regression, its extent and tumor-infiltrating lymphocyte (TILs), on result of sentinel lymph node (SLN) biopsy, 5-year melanoma-specific survival (MSS), and relapse-free survival (RFS). We included all patients with cutaneous melanoma who underwent SLN biopsy at the Melanoma Center of the University of Brescia, following the Italian Association of Medical Oncology National guidelines from January 2008 to August 2018. Regression and its extent (<75 or ≥75%) and the presence of TILs were reevaluated by a trained dermatopathologist, adhering to the 2017 College of American Pathologists Cancer Protocol for Skin Melanoma. These patients were followed up for 5 years. Our study uncovered significant associations between regression and male sex ( P  < 0.05), melanoma location on the trunk, upper limbs, and back ( P  = 0.001), ulceration ( P  < 0.05), lower Breslow thickness ( P  = 0.001), and the presence of lymphocytic infiltration (both brisk and nonbrisk) ( P  < 0.001). Regression and its extent, however, did not appear to affect SLN positivity ( P  = 0.315). Similarly, our data did not reveal a correlation between TILs and result of SLN biopsy ( P  = 0.256). When analyzing MSS and RFS in relation to the presence or absence of regression and TILs, no statistically significant differences were observed, thus precluding the need for logistic regression and Kaplan-Meier curve analysis. This study's findings underscore that regression and TILs do not appear to exert an influence on sentinel lymph node status, MSS, or RFS in our cohort of patients.
Arm (Tongji Hospital) All the participants will receive a paper-printed brochure introducing stress and stress management strategies and the instruction of using HUAWEI portable device at the recruitment. During the 3-month intervention phase, multiple formats of stress and stress management knowledge educations will be sent by the health educator on weekly basis. The participants will have personalized stress management nursing coaching and assistance of building up new life habits, they will be also encouraged to submit a weekly questionnaire for self-evaluation. Finally, participants from Tongji hospital will be involved in a social network to share their experience anonymously and gain knowledge from the group chat.
Colchicine 0.5 mg po once daily for 180 days. After the Day - 180 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
BACKGROUND: Ischemia-reperfusion (I/R) injury is a major factor in liver damage following hepatic resection and liver transplantation, with anesthetics demonstrating the ability to shield organs from this type of injury.
METHODS: Hypoxia-reoxygenation (H/R) was used to create in vitro I/R hepatocyte cell injury models. The CCK-8 assay, flow cytometer, LDH assay, and ELSIA were utilized to assess hepatocyte injury. The in vivo I/R injury rat model was then built. HE and TUNEL staining were used to assess liver tissue damage. Western-blot was applied to assess the activation of the MAPK/ERK pathway.
RESULTS: Remimazolam (RMZL) remarkably improved cell viability and decreased apoptosis in H/R-induced hepatocyte injury. RMZL reduced the release of H/R-induced inflammatory mediators (TNF-α and IL-6) as well as LDH levels. We also discovered that RMZL inhibited p38 and ERK1/2 phosphorylation in vivo and in vitro. The stimulation of MAPK/ERK, on the other hand, abolished RMZL's anti-inflammation effects in H/R-induced hepatocyte injury. Furthermore, RMZL reduced liver tissue injury in I/R rats.
CONCLUSION: RMZL prevented hepatic I/R damage by inhibiting MAPK/ERK signaling.
Cross-kingdom RNA interference (RNAi) is a crucial mechanism in host-pathogen interactions, with RNA-dependent RNA polymerase (RdRP) playing a vital role in signal amplification during RNAi. However, the role of pathogenic fungal RdRP in siRNAs generation and the regulation of plant-pathogen interactions remains elusive. Using deep sequencing, molecular, genetic, and biochemical approaches, this study revealed that VmRDR2 of Valsa mali regulates VmR2-siR1 to suppress the disease resistance-related gene MdLRP14 in apple. Both VmRDR1 and VmRDR2 are essential for the pathogenicity of V. mali in apple, with VmRDR2 mediating the generation of endogenous siRNAs, including an infection-related siRNA, VmR2-siR1. This siRNA specifically degrades the apple intracellular LRR-RI protein gene MdLRP14 in a sequence-specific manner, and overexpression of MdLRP14 enhances apple resistance against V. mali, which can be suppressed by VmR2-siR1. Conversely, MdLRP14 knockdown reduces resistance. In summary, this study demonstrates that VmRDR2 contributes to the generation of VmR2-siR1, which silences the host's intracellular LRR protein gene, thereby inhibiting host resistance. These findings offer novel insights into the fungi-mediated pathogenicity mechanism through RNAi.